Crucell and DSM Biologics Announce Second PER.C6 Licensing Agreement With MorphoSys
August 17, 2006 02:22 ET
|
Crucell N.V.
LEIDEN, Netherlands and SITTARD, Netherlands, Aug. 17, 2006 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Nasdaq:CRXL) (Swiss Exchange:CRX) and technology partner DSM Biologics today...
Crucell to Release Q2 2006 Earnings on Tuesday, August 29, 2006
August 15, 2006 08:24 ET
|
Crucell N.V.
LEIDEN, Netherlands, Aug. 15, 2006 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Nasdaq:CRXL) (Swiss Exchange:CRX) today announced that it will release its financial results for the second...
Crucell Announces PER.C6 Licensing Agreement with Tibotec
November 23, 2005 02:06 ET
|
Crucell N.V.
LEIDEN, Netherlands, Nov. 23, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has signed a PER.C6(r) license agreement with...
Crucell Teams up with ACE BioSciences and Harvard to Accelerate Bacterial Antibody Program
November 02, 2005 02:12 ET
|
Crucell N.V.
LEIDEN, Netherlands, Nov. 02, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has licensed bacterial antigens from ACE BioSciences...
Crucell to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference, November 8
November 01, 2005 08:20 ET
|
Crucell N.V.
LEIDEN, Netherlands, Nov. 01, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) today announced that its Chief Financial Officer, Leonard Kruimer CPA, will...
Crucell N.V: Tokyo Infectious Diseases Forum Highlights Strategies to Combat Flu and Other Pandemics
October 20, 2005 02:10 ET
|
Crucell N.V.
Vaccines and therapies, including antibody preparations, have to be
developed in short timeframes;
Global cooperation essential, as with SARS
TOKYO,...
Crucell and DSM Announce PER.C6 Licensing Agreement with IQ Corporation for Production of Monoclonal Antibodies against Anthrax
October 19, 2005 02:12 ET
|
Crucell N.V.
LEIDEN and SITTARD, Netherlands, Oct. 19, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today...
Crucell Announces Third Quarter 2005 Results
October 17, 2005 08:08 ET
|
Crucell N.V.
LEIDEN, Netherlands, Oct. 17, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) today announced its financial results for the third quarter and for the nine...
Crucell N.V.: Merck and Co., Inc. Exercises Option on PER.C6 License for Adenovirus-based Vaccine Against Hepatitis C
October 10, 2005 02:17 ET
|
Crucell N.V.
LEIDEN, Netherlands, Oct. 10, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that Merck & Co., Inc. (NYSE:MRK) has exercised its option...
Crucell to Release Third Quarter Results on Monday, October 17
October 03, 2005 08:36 ET
|
Crucell N.V.
LEIDEN, Netherlands, Oct. 3, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Nasdaq:CRXL) (Euronext:CRXL) today announced that it will release its financial results for the third...